STriTuVaD Newsletter - November 2019


Closing remarks...

November newsletter will also be the last of this year; 2019 has been challenging yet generous. A year of intense work rewarded with positive feedbacks along the way. Enjoy our latest updates before the next issue in 2020.


In this issue: 

- In Silico Research at the Joint Research Centre: interview with Andrew Worth and Alicia Paini - IDRI submits dossier for phase IIB testing of ID93+GLA-SE vaccine - STriTuVaD, TBVAC2020 and EMI-TB together for collaborative research and innovation of the TB vaccine pipeline - Strituvad partners meet in Luxembourg - First review meeting for Strituvad: positive feedbacks

- Related News

- Upcoming Events

In Silico Research at the Joint Research Centre: interview with Andrew Worth and Alicia Paini

Today we meet Andrew Worth, Senior Scientific Officer and Group Leader at the European Commission’s Joint Research Centre in Ispra (IT), and Alicia Paini, researcher in the same group who specialises in physiologically based kinetics model to evaluate the toxicity of chemicals.

Q: Can you tell us something about you, your background, and your role in your organisation?

Alicia Paini: We work at the Joint Research Centre (JRC), which is the European Commission's science and knowledge service. The role of the JRC is to support EU policy makers with independent scientific evidence throughout the whole policy cycle. As scientific officers within the JRC, we work at the science-policy interface, in particular in relation to policies on chemical safety, consumer protection, the environment, and on the protection of the animals ... (See more)

Q: What are, in your opinion, the grand challenges associated with the use of predictive models in the regulatory evaluation of new medical products?

Andrew Worth: This challenge is partly scientific, relating to the availability and quality of relevant data, but also social and psychological (trust in the model validation process; new and unfamiliar ways of assessing and managing risks). In relation to the evaluation of new medical products, the regulatory framework needs to allow for the use of modelling and simulation (M&S), and this needs to ... (See more)

Q: What do you believe could accelerate the adoption of In Silico Trials technologies?

Andrew Worth: A political will to develop a harmonised regulatory framework in the major economic regions, particularly in the EU and US. It is necessary to develop standards and guidelines that are accepted at an international level (hence the importance of international collaboration). We also collaborate with the Avicenna Alliance, who are doing a lot to promote this vision.

> READ THE FULL INTERVIEW

IDRI submits dossier for phase IIB testing of ID93+GLA-SE vaccine

The clinical dossier for a phase IIB, double-blind, randomized clinical trial to evaluate the safety and tolerability of ID93+GLA-SE as an adjunct to standard TB treatment has been prepared and submitted on... Read more





STriTuVaD, TBVAC2020 and EMI-TB together for collaborative research and innovation of the TB vaccine pipeline

The workshop took place in Bruxelles on the 8th of October and brought together scientists, policy makers, funders and other key stakeholders to discuss... Keep Reading



Internal meeting for STriTuVaD partners in Luxembourg

At the end of September, part of our consortium met in Luxembourg for a general internal meeting before the official appointment with the European Commission for the first project review. 



First review meeting for Strituvad: very positive feedbacks

Breaking news: we just received official and positive feedbacks from our first review meeting with the EU Commission in Luxembourg. Thanks to all partners for the good work!


Related News

Upcoming events

International Conference on Bioinformatics and Biomedicine18-21 Nov. 2019, San Diego, USA Partner of our consortium will attend and present contributions to the 3rd International Workshop on Computational Methods for the Immune System Function

19 views

© 2018-2023 STRITUVAD